Myovant readies NDA #3 as relugolix sails to its 5th positive PhIII — this time in endometriosis
Myovant $MYOV is on a roll.
In the last few days the biotech spawned on Vivek Ramaswamy’s Roivant platform has posted a positive readout on prostate cancer for their drug relugolix, followed by a priority review reward from the FDA. It’s got another NDA on uterine fibroids lined up. And now it has posted its second round of promising pivotal results for endometriosis, setting the stage for NDA number 3.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 124,600+ biopharma pros reading Endpoints daily — and it's free.